专利号:US-6548276-B2 优先权日:2000-09-06 标题:Enhanced in vitro synthesis of active proteins containing disulfide bonds 发明人:SWARTZ JAMES ROBERT; KIM DONG-MYUNG 权利人:UNIV LELAND STANFORD JUNIOR 摘要:Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions, pre-treatment and redox buffering of the reaction mix is performed in order to optimize the redox potential. Exogenous enzymes that enhance protein folding and disulfide bond formation may also be added to the reaction.
专利号:US-2024067694-A1 优先权日:2021-01-04 标 题:Synthesis of teduglutide 发明人:GANGA RAMU VASANTHAKUMAR; PATIL NITIN; SUVARNA DEEPA SHANKAR 权利人:BIOCON LTD 摘要:The present invention provides for novel synthetic approach of solid phase synthesis of peptides with C-terminal Aspartic acid by anchoring the side chain carboxylic group of aspartic acid to the solid support to avoid the formation of various impurities and thus resulting in higher yield and ease the purification process. The present invention further provides the usage of free amino acids and reducing agents as antioxidants in the cleavage cocktail to negate the formation of oxidative impurities formed during the global cleavage and isolation of the peptide from solid support.
专利号:US-2019177392-A1 优先权日:2014-09-23 标 题 :Synthesis of glp-1 peptides 发明人:PENIAS NAVON SHARON; NAVEH SHIRLY; VASILEIOU ZOI; BARLOS KONSTANTINOS 权利人:NOVETIDE LTD 摘要:Disclosed are processes for the synthesis of GLP-1 peptides, such as liraglutide and semaglutide, and a process for purifying liraglutide.
专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:US-7871794-B2 优先权日:2007-01-18 标 题:Enhanced cell-free synthesis of active proteins containing disulfide bonds 发明人:KNAPP KURTIS G; SWARTZ JAMES ROBERT 权利人:UNIV LELAND STANFORD JUNIOR 摘要:Compositions and methods are provided for the enhanced in vitro synthesis of active polypeptides containing disulfide bonds. In certain embodiments of the invention, the reaction mix includes a biological extract derived from a bacterial cell in which the glutathione reductase gene has been inactivated, which is pre-treated with a low concentration of a sulfhydryl inactivating agent.
专利号:US-9475837-B2 优先权日:2011-12-23 标题 :Process for the synthesis of therapeutic peptides 发明人:HURLEY FIONN; WEGNER KATARZYNA; FOLEY PATRICK 权利人:IPSEN MFG IRELAND LTD 摘要:The present invention relates to a process for the large-scale synthesis of therapeutic peptides using a Sieber Amide resin, which comprises solid-phase Fmoc-chemistry.
1: Honda K. Glucagon-related peptides and the regulation of food intake in chickens. Anim Sci J. 2016 May 6. doi: 10.1111/asj.12619. [Epub ahead of print] Review. doi: 10.1042/BST20150244. Review. doi: 10.1016/j.tem.2016.03.004. Epub 2016 Apr 6. Review. doi: 10.4103/2230-8210.176351. Review. 9: Peng H, Want LL, Aroda VR. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Curr Diab Rep. 2016 May;16(5):44. doi: 10.1007/s11892-016-0728-4. Review. doi: 10.1177/0269881115625496. Epub 2016 Jan 22. Review. doi: 10.1155/2015/171742. Epub 2015 Dec 15. Review. 15: Giorgino F, Bonadonna RC, Gentile S, Vettor R, Pozzilli P. Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of lixisenatide and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev. 2016 Jan 20. doi: 10.1002/dmrr.2775. [Epub ahead of print] Review. doi: 10.17305/bjbms.2015.794. Review.
合成参考文献
参考文献:10.1016/j.jmb.2010.02.012 摘要:Andersen CB, Hicks MR, Vetri V, Vandahl B, Rahbek-Nielsen H, Thøgersen H, Thøgersen IB, Enghild JJ, Serpell LC, Rischel C, Otzen DE. Glucagon fibril polymorphism reflects differences in protofilament backbone structure. J Mol Biol. 2010 Apr 09;397(4):932–46. doi: 10.1016/j.jmb.2010.02.012. 参考文献:10.1016/j.jim.2011.06.020 摘要:Soderstrom CI, Spriggs FP, Song W, Burrell S. Comparison of four distinct detection platforms using multiple ligand binding assay formats. J Immunol Methods. 2011 Aug 31;371(1-2):106–13. doi: 10.1016/j.jim.2011.06.020. 参考文献:10.4161/isl.3.5.16427 摘要:Al-Salam S, Rashed H, Adeghate E. Diabetes mellitus is associated with an increased expression of resistin in human pancreatic islet cells. Islets. 2011 Sep;3(5):246–9. doi: 10.4161/isl.3.5.16427. 摘要:Ortiz-Muñoz L, Rodriguez-Ospina LF, Figueroa-Gonzalez M. Hyperinsulinemic-euglycemic therapy for intoxication with calcium channel blockers. Bol Asoc Med P R. 2005 Jul;97(3 Pt 2):182–9. 参考文献:10.1016/j.jmb.2005.09.100 摘要:Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol. 2006 Jan 20;355(3):501–23. doi: 10.1016/j.jmb.2005.09.100.